Quartz·1 min read·medium
Abivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
✦AI Summary
French biotech firm Abivax has raised $920 million to independently fund the U.S. commercial launch of its bowel disease drug, obefazimod. The company plans to manage the rollout through 2029 without relying on external partners.
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in